|
Volumn 5, Issue 5, 2007, Pages 769-771
|
Highlights of the third international workshop on HIV and hepatitis coinfection. June 7-9, 2007, Paris, France
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADEFOVIR;
ANTIRETROVIRUS AGENT;
ANTIVIRUS AGENT;
DIDANOSINE;
EMTRICITABINE;
ENTECAVIR;
INTERFERON;
LAMIVUDINE;
PEGINTERFERON;
PEGINTERFERON ALPHA2A;
PROTEINASE INHIBITOR;
RIBAVIRIN;
TELAPREVIR;
TELBIVUDINE;
TENOFOVIR DISOPROXIL;
UNCLASSIFIED DRUG;
VIRUS RNA;
ADD ON THERAPY;
ANTIBIOTIC RESISTANCE;
CAUSE OF DEATH;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
COMORBIDITY;
CONFERENCE PAPER;
CONSENSUS DEVELOPMENT;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG RESPONSE;
DRUG SAFETY;
DRUG WITHDRAWAL;
FATTY LIVER;
GENETIC VARIABILITY;
HEPATITIS B;
HEPATITIS C;
HEPATITIS C VIRUS;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INDIVIDUALIZATION;
LIVER CIRRHOSIS;
LIVER FIBROSIS;
LIVER HYPERPLASIA;
LIVER INJURY;
MONOTHERAPY;
OUTCOMES RESEARCH;
PRACTICE GUIDELINE;
SIDE EFFECT;
TREATMENT PLANNING;
VIRAL GENETICS;
VIRUS CELL INTERACTION;
VIRUS REPLICATION;
WORKSHOP;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
HEPATITIS B, CHRONIC;
HEPATITIS C;
HEPATITIS, VIRAL, HUMAN;
HIV INFECTIONS;
HUMANS;
INTERFERONS;
RIBAVIRIN;
|
EID: 35348936097
PISSN: 14787210
EISSN: 17448336
Source Type: Journal
DOI: 10.1586/14787210.5.5.769 Document Type: Conference Paper |
Times cited : (2)
|
References (3)
|